Latest news with #Sol-GelTechnologies
Yahoo
23-05-2025
- Business
- Yahoo
Sol-Gel Reports First Quarter 2025 Results
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase of $3.5 million was primarily attributed to an increase of $3.6 million due to expenses associated with supplier-led manufacturing development to support future commercialization of SGT-610, an increase of $0.5 million related to the commercialization of EPSOLAY and TWYNEO in territories outside of the U.S., offset by a decrease of $0.5 million in clinical trial expenses related to SGT-610. General and administrative expenses were $1.3 million compared to $1.8 million for the same period in 2024. The decrease of $0.5 million was mainly attributed to a decrease in payroll and stock-based compensation expenses due to cost measures being taken in 2024. Sol-Gel reported a net loss of $8.8 million for the first quarter of 2025 and of $3.2 basic and diluted loss per share, compared to a net loss of $6.3 million and a loss of $2.3 per basic and diluted share for the same period in 2024. As of March 31, 2025, Sol-Gel had $16.9 million in cash, cash equivalents, and deposits and no marketable securities for a total balance of $16.9 million. The Company expects its cash resources to fund cash requirements into the first quarter of 2027. About Sol-Gel Technologies Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. The Company's pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and also includes topical drug candidate SGT-210 under investigation for the treatment of rare skin keratodermas. For additional information, please visit Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to our expected cash runway. In some cases, you can identify forward-looking statements by terminology such as 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'expect,' 'predict,' 'potential,' or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management's current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, our ability to enter into further collaborations, lower than anticipated annual revenue income from new collaborations, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators' ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators' ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators' ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving Israel with other parties. These factors and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ('SEC') on April 29, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release. SOL-GEL TECHNOLOGIES LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands) (Unaudited) December 31, March 31, 2024 2025 Assets CURRENT ASSETS: Cash and cash equivalents $ 19,489 $ 16,890 Bank deposits 12 12 Marketable securities 4,425 - Accounts receivables 3,595 3,883 Prepaid expenses and other current assets 3,774 2,647 TOTAL CURRENT ASSETS 31,295 23,432 NON-CURRENT ASSETS: Restricted long-term deposits and cash equivalents 1,291 1,293 Long-term receivables 1,024 518 Property and equipment, net 202 183 Operating lease right-of-use assets 1,426 1,332 Other long-term assets 13 - Funds in respect of employee rights upon retirement 595 305 TOTAL NON-CURRENT ASSETS 4,551 3,631 TOTAL ASSETS $ 35,846 $ 27,063 Liabilities and shareholders' equity CURRENT LIABILITIES: Accounts payable $ 1,265 $ 438 Other accounts payable 3,590 3,702 Current maturities of operating leases 430 433 TOTAL CURRENT LIABILITIES 5,285 4,573 LONG-TERM LIABILITIES: Operating leases liabilities 878 746 Liability for employee rights upon retirement 833 363 Other long-term Liability 1,209 TOTAL LONG-TERM LIABILITIES 1,711 2,318 TOTAL LIABILITIES 6,996 6,891 SHAREHOLDERS' EQUITY: Ordinary shares, NIS 0.1 par value – authorized: 5,000,000 as of December 31, 2024 and March 31, 2025, respectively; issued and outstanding: 2,785,762 as of December 31, 2024 and March 31, 2025, respectively (*) 774 774 Additional paid-in capital 258,959 259,089 Accumulated deficit (230,883) (239,691) TOTAL SHAREHOLDERS' EQUITY 28,850 20,172 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 35,846 $ 27,063 (*) All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split. SOL-GEL TECHNOLOGIES LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands) (Unaudited) Three months endedMarch 31 2024 2025 LICENSE REVENUES $ 466 $ 1,031 RESEARCH AND DEVELOPMENT EXPENSES 5,345 8,843 GENERAL AND ADMINISTRATIVE EXPENSES 1,833 1,257 OPERATING LOSS 6,712 9,069 FINANCIAL INCOME,net (368) (261) LOSS FOR THE PERIOD 6,344 8,808 BASIC AND DILUTED LOSS PER ORDINARY SHARE 2.3 3.2 WEIGHTED AVERAGE NUMBER OF SHARES*OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (*) 2,785,762 2,785,762 (*)All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split. Sol-Gel Contact:Eyal Ben-OrChief Financial Officerir@ Sol-Gel Technologies in to access your portfolio
Yahoo
02-05-2025
- Business
- Yahoo
This Sol-Gel Technologies Insider Increased Their Holding In The Last Year
Looking at Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold. Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Notably, that recent purchase by Moshe Arkin is the biggest insider purchase of Sol-Gel Technologies shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$0.77). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Moshe Arkin was the only individual insider to buy shares in the last twelve months. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! See our latest analysis for Sol-Gel Technologies There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Sol-Gel Technologies insiders own about US$14m worth of shares (which is 65% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Sol-Gel Technologies. That's what I like to see! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 2 warning signs for Sol-Gel Technologies and we suggest you have a look. Of course Sol-Gel Technologies may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Globe and Mail
10-03-2025
- Business
- Globe and Mail
Rosacea Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight
"Rosacea Treatment Market" Rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others. (Albany, USA) DelveInsight's ' Rosacea Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of Rosacea, including historical and forecasted epidemiology, as well as Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. The latest healthcare forecast report delivers a comprehensive analysis of Rosacea, offering critical insights into prevalence, revenue trends, and evolving Rosacea treatment options. The report discusses key statistics, including current and projected market sizes, while also delving into Rosacea symptoms and their impact on patients' quality of life. It evaluates the progress and effectiveness of emerging therapies for Rosacea alongside an in-depth examination of the clinical trial landscape. This includes a detailed review of ongoing and upcoming studies that are set to shape the future of Rosacea treatment. With its rich data and forward-looking insights, this report serves as an indispensable resource for understanding market dynamics and advancements in the field of Rosacea. Some of the key insights of Rosacea Market Report: The rosacea market size is expected to experience significant growth during the forecast period (2024–2034). This growth is a direct consequence of various market-driving factors such as improving access to diagnosis and treatment, increased awareness and research, advancements in treatment options, and increasing prevalence of rosacea. Emerging therapies for rosacea include AIV001, TP-04, B244, and others. Key rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others. In the US, the prevalence of rosacea is increasing, with around 16 million Americans affected, according to the American Academy of Dermatology. In the UK, rosacea affects approximately 2 per 1,000 persons, with prevalence rates ranging from 0.10% to 22%. In Germany, the prevalence of rosacea was around 12%, with erythematotelangiectatic (ETR) and papulopustular (PPR) subtypes accounting for 9% and 3%, respectively. About 18% of diagnosed cases were in individuals aged 18-30 years. Rosacea is more common in females, with nearly 90% of cases in women compared to 15% in men. The most common subtypes were erythematotelangiectatic (60%), papulopustular (30%), phytates (20%), and ocular (40%). The rosacea treatment market is currently led by EPSOLAY, a product by Sol-Gel Technologies and Galderma, which is expected to expand in the coming years. On November 5, 2024, the FDA approved minocycline hydrochloride extended-release capsules (DFD-29, Emrosi) for treating inflammatory lesions caused by rosacea in adults. This approval followed positive Phase 3 trial results. Rosacea Overview: Rosacea is a chronic skin condition characterized by facial erythema (redness) that affects around 1 in 10 people worldwide. Rosacea symptoms vary widely, with some individuals experiencing persistent redness, visible blood vessels, and swollen, red bumps that resemble acne. The condition can be categorized into four types: erythematotelangiectatic rosacea, papulopustular rosacea (PPR), phymatous rosacea, and ocular rosacea. Many patients exhibit symptoms of more than one type, making diagnosis and treatment more complex. Papulopustular rosacea, also known as inflammatory rosacea or type-2 rosacea, is commonly mistaken for acne due to the presence of 'whitehead' pustules and red, swollen bumps, particularly on the cheeks, chin, and forehead. This subtype of rosacea often flares up for weeks to months before subsiding temporarily. While the exact causes remain unclear, researchers suggest that genetic predisposition, immune responses to Bacillus oleronius and H. pylori infections, overproduction of cathelicidin protein, or Demodex mites living on the skin may play a role in its development. The diagnosis of rosacea is largely based on patient history and physical examination. However, its symptoms can be confused with other skin conditions such as adult acne vulgaris, photodermatitis, seborrheic dermatitis, or contact dermatitis. This overlap of rosacea symptoms highlights the need for careful evaluation to ensure accurate diagnosis and treatment. The therapeutic landscape of rosacea includes various drug classes used to treat rosacea, with treatments tailored based on the severity and subtype of the condition. The primary options include topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids. For moderate cases of papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Maintenance therapy often involves topical agents like metronidazole. Among topical treatments, retinoids such as tretinoin, tazarotene, and adapalene are commonly prescribed to reduce erythema, papules, pustules, and telangiectasia. Tretinoin, one of the most affordable and widely used topical retinoids, is often the drug of choice for treating rosacea symptoms. Topical antibiotics, including metronidazole, clindamycin, erythromycin, azelaic acid, benzoyl peroxide, and sulfacetamide, are also applied to the skin to combat surface bacteria and reduce inflammation. Among the new drugs for rosacea, EPSOLAY is the only US FDA-approved topical treatment for rosacea, highlighting the growing focus on targeted therapies to address unmet needs in this space. With ongoing advancements, researchers continue to explore innovative drugs to treat rosacea, offering hope for improved management strategies and better quality of life for patients. Rosacea Epidemiology: The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. The Rosacea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total prevalent cases of rosacea Diagnosed prevalent cases of rosacea Type-specific diagnosed prevalent cases of rosacea Treated cases of rosacea Download the report to understand which factors are driving Rosacea epidemiology trends @ Rosacea Epidemiology Forecast Rosacea Drugs Uptake and Pipeline Development Activities: The drug uptake section examines the adoption rates of newly launched and upcoming Rosacea drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section offers a comprehensive look at the factors influencing the acceptance and success of Rosacea treatments in the market. In addition, the therapeutics assessment section highlights the Rosacea drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a market share comparison among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption. The report further explores the Rosacea pipeline, providing insights into therapeutic candidates at different stages of development. It identifies the key companies involved in creating targeted Rosacea treatments. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for Rosacea. Rosacea Market Outlook: The Rosacea market is poised for significant changes and growth in the coming years, driven by ongoing research and development efforts to address unmet medical needs. Current treatment options for rosacea, particularly for papulopustular rosacea, include approved and off-label therapies belonging to therapeutic categories, such as topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids. Topical antibiotics, the most commonly prescribed class of rosacea for all sexes and age groups, include metronidazole, clindamycin, erythromycin, and azelaic acid, with metronidazole leading in prescription volume. Oral TCAs like tetracycline, minocycline, and doxycycline (Oracea) are effective anti-inflammatory agents, with tetracycline being the most prescribed, followed by minocycline and doxycycline. While oral retinoids, such as isotretinoin, are often used as an off-label therapy, studies suggest that low-dose isotretinoin may offer better outcomes compared to doxycycline in some instances. Despite the availability of these therapies, there remains a significant need for novel and more effective treatments to manage rosacea symptoms and improve patient outcomes. Encouragingly, many companies are developing innovative drugs to meet these unmet needs, which is expected to drive market growth. According to DelveInsight, the rosacea market in the 7MM (US, EU5, and Japan) is projected to experience substantial growth during the study period of 2020–2034, as advancements in research and therapeutic innovation continue to shape the market landscape. To learn more about Rosacea therapies and Compsnies working in the treatment market, visit @ Rosacea Medication and Pipeline Rosacea Market Drivers: The increasing prevalence of rosacea, driven by factors like environmental changes and lifestyle, is pushing the demand for treatments. Ongoing research and introducing new, more effective medications are encouraging growth in the rosacea market. Rosacea Market Barriers: The absence of a permanent cure for rosacea can lead to long-term patient frustration, affecting market confidence. The stigma surrounding visible skin conditions may discourage people from seeking treatment, limiting market potential. Scope of the Rosacea Market Report: Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Rosacea Companies: Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others. Key Rosacea Therapies: AIV001, TP-04, B244, and others. Rosacea Therapeutic Assessment: Rosacea currently marketed, and Rosacea emerging therapies Rosacea Market Dynamics: Rosacea market drivers and Rosacea market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Rosacea Unmet Needs, KOL's views, Analyst's views, Rosacea Market Access and Reimbursement To learn more about Rosacea companies working in the treatment market, visit @ Rosacea Clinical Trials and Therapeutic Assessment Table of Contents: 1. Rosacea Market Report Introduction 2. Executive Summary for Rosacea 3. SWOT analysis of Rosacea 4. Rosacea Patient Share (%) Overview at a Glance 5. Rosacea Market Overview at a Glance 6. Rosacea Disease Background and Overview 7. Rosacea Epidemiology and Patient Population 8. Country-Specific Patient Population of Rosacea 9. Rosacea Current Treatment and Medical Practices 10. Rosacea Unmet Needs 11. Rosacea Emerging Therapies 12. Rosacea Market Outlook 13. Country-Wise Rosacea Market Analysis (2020–2034) 14. Rosacea Market Access and Reimbursement of Therapies 15. Rosacea Market Drivers 16. Rosacea Market Barriers 17. Rosacea Appendix 18. Rosacea Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight: DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Yahoo
07-02-2025
- Business
- Yahoo
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. Given this risk, we thought we'd take a look at whether Sol-Gel Technologies (NASDAQ:SLGL) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. Check out our latest analysis for Sol-Gel Technologies You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In September 2024, Sol-Gel Technologies had US$28m in cash, and was debt-free. Importantly, its cash burn was US$17m over the trailing twelve months. Therefore, from September 2024 it had roughly 20 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. Importantly, if we extrapolate recent cash burn trends, the cash runway would be noticeably longer. Depicted below, you can see how its cash holdings have changed over time. At first glance it's a bit worrying to see that Sol-Gel Technologies actually boosted its cash burn by 16%, year on year. Given that it boosted operating revenue by a stand-out 870% in the same period, we think management are simply more focussed on growth than preserving cash. Sometimes you need to spend money to make money! We think it is growing rather well, upon reflection. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years. Sol-Gel Technologies seems to be in a fairly good position, in terms of cash burn, but we still think it's worthwhile considering how easily it could raise more money if it wanted to. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Since it has a market capitalisation of US$21m, Sol-Gel Technologies' US$17m in cash burn equates to about 80% of its market value. That suggests the company may have some funding difficulties, and we'd be very wary of the stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Sol-Gel Technologies' revenue growth was relatively promising. Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. Separately, we looked at different risks affecting the company and spotted 3 warning signs for Sol-Gel Technologies (of which 1 is potentially serious!) you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
